Clicky

BetterLife Pharma Inc(NPAU)

Description: BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for the treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream that has completed Phase II clinical trials for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.


Keywords: Biotechnology Pain Major Depressive Disorder Cervical Cancer Neurodegenerative Disorders Interferon Papillomavirus Treatment Of Major Depressive Disorder Viral Infections Human Papillomavirus Infection Cervical Intraepithelial Neoplasia Mental Disorders Intraepithelial Neoplasia Respiratory Viral Infections Treatment Of Mental Disorders

Home Page: www.abetterlifepharma.com

1275 West 6th Avenue
Vancouver, BC V6H 1A6
Canada
Phone: 604 221 0595


Officers

Name Title
Dr. Ahmad Doroudian Ph.D. Founder, CEO & Chairman
Ms. Moira Ong C.A., CPA, CA, CFA Chief Financial Officer
Dr. Hooshmand Sheshbaradaran Ph.D. Chief Operating Officer
Dr. Stephen Sangha Corporate Development Advisor
Mr. Scott Rudge Ph.D. Head of CMC
Anthony Calandra Ph.D. Head of Regulatory
Dr. Abdi Ghaffari Ph.D. Head of Preclinical & Toxicology

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 12.4106
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: January
Full Time Employees: 0
Back to stocks